ECTS2014 Poster Presentations Bone development/growth and fracture repair (55 abstracts)
Serum serotonin: useful for the assessment of the bone metabolism status?
Catalina Poiana 1, , Mara Carsote 1, , Valentin Radoi 1 , Alexandra Mihai 2 , Andreea Geleriu 2 , Cristina Capatana 1, , Raluca Trifanescu 1, & Daniela Opris 1,
1Davila UMPh, Bucharest, Romania; 2Parhon National Institute of Endocrinology, Bucharest, Romania; 3Sfanta Maria Hospital, Bucharest, Romania.
Introduction: Atypical markers will provide interesting information in order to assess the bone metabolism. Serotonin has a dual action related to the bone and its serum level is the easiest to use in daily clinical practice also the exact value is not very well described up to this moment.
Aim: We correlate to serum levels of serotonin with different results of clinical bone health evaluation in menopausal women.
Materials and methods: A transversal study enrolled menopausal women with no previous specific medication for osteoporosis. The study was conducted in Parhon National Institute of Endocrinology, Bucharest, Romania. No patient with previous neuroendocrine tumor or carcinoid syndrome was enrolled. The serum serotonin (ELISA) had normal levels between 40 and 400 ng/ml. The bone evaluation was performed by central DXA (GE Lunar Prodigy) and Heel Quantitative Ultrasound (Achilles Insight). The WHO groups based on central DXA were formed. The SPSS21 was used for statistic. Statistical significance was at P value <0.05.
Results: 132 women had mean age of 56.3 years, and mean left Achilles stiffness index (ASI) of 80; mean lumbar bone mineral density (BMD) was 1.04 g/cm2. 52 subjects had normal DXA, 62 patients had osteopenia, and 18 women had osteoporosis. The mean serotonin (of 159 ng/ml) was in osteoporosis groups of 147.8 ng/ml, in osteopenia of 164.2 ng/ml, and in women with normal DXA of 156.5 ng/ml. The linear correlation between serotonin levels and lumbar BMD, as well as ASI was not statistical significant.
Discussion: The serotonin has not yet been placed in current clinical practice, but this represents an intro into two different domains: the non-metastatic carcinoid bone loss, and the anti-depression medication (including serotonin mediators) and fracture risk.
Conclusion: No trend line was detected in serotonin levels in patients with different levels of BMD.
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more